The PARP inhibitor Rucaparib has been included in three single arm studies: TRIUMPH (NCT03413995) for hormone sensitive metastatic prostate cancer, TRITON2 (NCT02952534) for castration resistant metastatic prostate cancer, and ROAR (NCT03533946) for non-metastatic castration resistant prostate cancer. The gene discussed is PARP1; the disease is metastatic prostate carcinoma.